Biohaven Ltd. (BHVN)
NYSE: BHVN
· Real-Time Price · USD
15.66
1.43 (10.05%)
At close: Aug 15, 2025, 12:50 PM
10.05% (1D)
| Bid | 15.61 |
| Market Cap | 1.66B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -888.6M |
| EPS (ttm) | -7.46 |
| PE Ratio (ttm) | -2.1 |
| Forward PE | -2.32 |
| Analyst | Buy |
| Ask | 15.72 |
| Volume | 1,474,844 |
| Avg. Volume (20D) | 2,014,609 |
| Open | 14.51 |
| Previous Close | 14.23 |
| Day's Range | 14.36 - 15.69 |
| 52-Week Range | 12.79 - 55.70 |
| Beta | 3.50 |
About BHVN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BHVN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BHVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Biohaven Ltd. is scheduled to release its earnings on
Nov 11, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+21.59%
Shares of several biotechnology stocks are trading...
Unlock content with
Pro Subscription
3 months ago
-19.53%
Biohaven shares are trading lower after the FDA's Office of Neuroscience extended the PDUFA date for the troriluzole new drug application for the treatment of spinocerebellar ataxia by three months to provide time for a full review of the company's recent submissions related to information requests from the agency.
